Skip to Content

Geron Corp GERN

Morningstar Rating
$1.96 +0.02 (1.03%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GERN is trading at a 40% discount.
Price
$1.94
Fair Value
$6.97
Uncertainty
Extreme
1-Star Price
$34.15
5-Star Price
$1.45
Economic Moat
Mdlp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GERN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.94
Day Range
$1.942.00
52-Week Range
$1.683.74
Bid/Ask
$1.96 / $1.97
Market Cap
$1.06 Bil
Volume/Avg
335,950 / 6.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3,425.77
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
107

Comparables

Valuation

Metric
GERN
PLRX
KROS
Price/Earnings (Normalized)
Price/Book Value
3.921.985.93
Price/Sales
3,425.77263.12
Price/Cash Flow
Price/Earnings
GERN
PLRX
KROS

Financial Strength

Metric
GERN
PLRX
KROS
Quick Ratio
3.6719.1917.29
Current Ratio
3.7519.5018.23
Interest Coverage
−22.71−138.17
Quick Ratio
GERN
PLRX
KROS

Profitability

Metric
GERN
PLRX
KROS
Return on Assets (Normalized)
−47.27%−22.35%−35.75%
Return on Equity (Normalized)
−71.83%−24.26%−38.87%
Return on Invested Capital (Normalized)
−59.79%−27.62%−37.47%
Return on Assets
GERN
PLRX
KROS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFdd$544.0 Bil
VRTX
Vertex Pharmaceuticals IncCtkhyy$108.7 Bil
REGN
Regeneron Pharmaceuticals IncQrrvnf$103.9 Bil
MRNA
Moderna IncXmmb$33.2 Bil
ARGX
argenx SE ADRHls$23.4 Bil
BNTX
BioNTech SE ADRDcblm$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncJxjnsq$18.9 Bil
BMRN
Biomarin Pharmaceutical IncBypqqty$16.7 Bil
RPRX
Royalty Pharma PLC Class AVlhdpv$13.5 Bil
INCY
Incyte CorpCzrzxg$13.2 Bil

Sponsor Center